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Abstract 
Hearing impairment is due to various causes including ototoxicity from aminoglycosides. The susceptibility to ami-
noglycosides increases in the presence of certain mitochondria gene mutations. There is unrestrained use of amino-
glycosides in many developing nations which may worsen the burden of hearing impairment in these countries but 
there is lack of data to drive required policy changes. Streptomycin (an aminoglycoside) is part of the drug regimen 
in re-treatment of tuberculosis. Exploring the impact of streptomycin ototoxicity in tuberculosis patients provides a 
unique opportunity to study aminoglycoside ototoxicity within the population thus providing data that can inform 
policy. Also, since streptomycin ototoxicity could adversely affect treatment adherence in tuberculosis patients this 
study could enable better pre-treatment counseling with subsequent better treatment adherence. Patients on tuber-
culosis re-treatment will be recruited longitudinally from Direct Observation Therapy-Short course centers. A baseline 
full audiologic assessment will be done before commencement of treatment and after completion of treatment. Early 
detection of ototoxicity will be determined using the American Speech and Hearing Association criteria and genetic 
analysis to determine relevant mitochondria gene mutations will be done. The incidence of ototoxicity in the cohort 
will be analyzed. Both Kaplan–Meier survival curve and Cox proportional hazards tests will be utilized to determine 
factors associated with development of ototoxicity and to examine association between genotype status and oto-
toxicity. This study will provide data on the burden and associated predictors of developing aminoglycoside induced 
ototoxicity. This will inform public health strategies to regulate aminoglycoside usage and optimization of treatment 
adherence and the management of drug-induced ototoxicity among TB patients. Furthermore the study will describe 
mitochondrial gene mutations associated with ototoxicity in the African population.
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Background
Hearing ability is one of the key human senses and it 
could be argued to be essential for satisfactory quality of 
life. Loss of hearing therefore, may be a major disability. 
This disability becomes more apparent in the communal 
cultural setting prevalent in many developing countries 
where hearing impaired people may suffer from social 
stigmatization and isolation. Hearing loss imposes signif-
icant social and economic disadvantages on both individ-
uals and communities. Hearing impaired children often 
experience delayed development of speech, language, and 
cognitive skills, causing slowed learning and difficult pro-
gress in school (WHO 2014). Among adults, impairment 
of hearing makes it difficult to obtain and keep employ-
ment (WHO 2014). Hearing loss occurs via multiple 
pathways,—inflammatory disease of the middle ear is 
the commonest cause in children (Adeyemo 2012a)—but 
ototoxicity is an increasing cause of hearing loss in devel-
oping countries.
According to the World Health Organization (WHO) 
majority of hearing impaired people resides in develop-
ing countries; while a number of etiological factors have 
been identified as a cause of the impairment in these 
countries, ototoxicity from both antibiotics and anti-
malarial drugs feature prominently (WHO 2014) and 
aminoglycoside antibiotics are the commonest cause 
of ototoxicity (WHO 1994). Irrational prescription of 
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aminoglycosides have been reported in many developing 
countries (Gwimile et al. 2012) and this unrestrained use 
may keep eliciting a huge burden of hearing impairment 
unless a significant policy change comes into effect in 
these countries. Unfortunately there is inadequate locally 
derived data to drive such a policy change.
Streptomycin, Amikacin, and Kanamycin are examples 
of aminoglycosides in the drug armamentarium against 
tuberculosis (Peloquin et al. 2004). Studying the strepto-
mycin induced ototoxicity in tuberculosis patients pro-
vides an excellent opportunity to monitor aminoglycoside 
ototoxicity within a developing country population.
Aminoglycoside induced ototoxicity
Ototoxicity is an irreversible side effect of aminoglyco-
sides (De Jager and Van Altena 2002), and could mani-
fest as either cochlea damage with permanent hearing 
loss or vestibular damage with dizziness, ataxia and/or 
nystagmus (Duggal and Sarkar 2007). This adverse effect 
is dose-dependent (De Jager and Van Altena 2002) and 
compounded by the narrow therapeutic range of amino-
glycosides and the wide inter-individual variability in the 
pharmacokinetics of the drug (Duggal and Sarkar 2007). 
Aminoglycoside ototoxicity is recognized by a distinctive 
pattern of hearing loss, the high frequency range (4000–
8000 Hz) is affected first with lower frequencies affected 
subsequently (Human et al. 2010).
Aminoglycosides cause degeneration of sensory cells 
in the cochlea; usually involving the basal turn initially 
before progressing to the cochlea apex. This is the basis 
for the initial high frequency hearing loss subsequently 
followed by hearing loss in the lower frequencies. There-
fore in the early stages of aminoglycoside ototoxicity 
conversational hearing might not be affected. Vestibu-
lar impairment occurs following damage to the vestibu-
lar sensory cells in the crista ampullaris and it manifests 
with ataxia and nystagmus. The subject complains of gait 
disturbances and oscillopsia (visual blurring with head 
movement) in the absence of prior existence of vertigo 
(Kisilevsky et al. 2004). All aminoglycosides exhibit toxic-
ity on both the cochlea and the vestibules but often not in 
equal proportions though tobramycin is known to affect 
both the cochlea and vestibules equally (Guan 2011). 
Aminoglycosides such as streptomycin and gentamycin 
are predominantly vestibulotoxic whereas neomycin and 
kanamycin are more toxic on the cochlea (Guan 2011).
The incidence of ototoxicity depends on the duration 
and dose of the aminoglycoside; reported incidence var-
ies widely from 28 to 37 % (Sturdy et al. 2011, Peloquin 
et al. 2004). However factors such as definitional criteria 
for hearing loss, methods of assessment, subject group 
and treatment parameters had influenced the reported 
incidence of ototoxicity (Xie et  al. 2011). Therefore 
the use of more sensitive testing criteria will probably 
increase the proportion of hearing loss detected in ami-
noglycoside exposure (Fausti et al. 1992).
Tuberculosis control
Tuberculosis is known to man since antiquity and it is still 
one of the leading infectious diseases in the world with a 
third of the world’s population already infected (Duggal 
and Sarkar 2007; Jones-López et  al. 2011). Nine million 
new cases of TB are diagnosed annually and the disease is 
responsible for more than two million deaths every year 
(Harries and Dye 2006; Adeyemo 2012b). Hopes of eradi-
cating TB had initially brightened with the discovery of 
streptomycin by Waksman in 1944 (Schacht 2004) how-
ever multiple factors including resource constraints, eco-
nomic crises, and recently HIV/AIDS pandemic had led 
to renewed surge in TB burden in many developing coun-
tries. The emergence of drug resistant TB strains are due 
to factors such as lack of adherence by patients to drug 
regimen, improper prescription, inadequate supply, and 
low quality drugs (Lienhardt et al. 2012). The proportion 
of drug resistant TB among TB cases have been increas-
ing worldwide (Sturdy et al. 2011); since the second-line 
drugs advocated by WHO for the management of drug 
resistant TB includes aminoglycosides there has been a 
corresponding upsurge in the usage of aminoglycosides.
A high proportion of TB patients fail to complete their 
initial treatment and thus require re-treatment with 
streptomycin based drug regimen—category II regimen 
(Jones-López et al. 2011). Indeed 10–20 % of the popu-
lations with TB in developing countries are commenced 
on streptomycin based anti-TB drugs regimen annually 
(Jones-López et  al. 2011) which involves daily strepto-
mycin injection for 2 months. The key side effect of long-
term administration of parenteral aminoglycosides is 
ototoxicity.
Single versus multiple dosing regimen
There have been previous attempts to reduce the toxici-
ties associated with aminoglycosides by varying the fre-
quency of dosage. Traditionally aminoglycosides have 
been given in Multiple Daily Doses (MDD) in either 8 or 
12 hourly doses to ensure therapeutic concentrations that 
could guarantee clinical success as well as preventing tox-
icities of the kidney or inner ear.
Single daily dosing (SDD) however might lead to 
greater clinical efficacy. SDD produces higher peak serum 
concentrations which increased the rate and proportion 
of the microbicidal activity (Ali and Goetz 1997). Moreo-
ver, the concept of saturation of aminoglycoside uptake 
into the renal proximal tubule cell also encouraged 
SDD practice with the intention of reducing associated 
nephrotoxicity (Rotstein and Mandell 2004). Additional 
Page 3 of 9Adeyemo et al. SpringerPlus  (2016) 5:758 
evidence which showed that laboratory animals manifest 
less toxicity on SDD rather than MDD (Ali and Goetz 
1997) and demonstration of saturation kinetics in the 
entry of aminoglycosides into the ear (Tran Ba Huy et al. 
1986) probably promoted adoption of SDD.
Meta-analyses of clinical trials comparing SDD and 
MDD showed superiority of SDD for bacteriologic 
eradication and a reduced incidence of nephrotoxic-
ity (Rotstein and Mandell 2004; Turnidge 2003). How-
ever assessment of ototoxicity in the meta-analyses did 
not show any clear trend as some clinical trials favored 
SDD while others favored MDD. No statistically signifi-
cant differences were seen between SDD and MDD in 
the data assessment of vestibular toxicity (Rotstein and 
Mandell 2004). The variability in techniques of evaluat-
ing ototoxicity in the trials and lack of standard definition 
of what constitutes “toxicity” between the trials may had 
accounted for the inconsistencies in the trial results (Rot-
stein and Mandell 2004). The simplicity of SDD (espe-
cially in out-patient set-up), cost advantages, and efficacy 
have made it the preferred dosage regimen in streptomy-
cin administration in TB control programs.
Auditory assessment in ototoxicity
There is no universal consensus on the most appropri-
ate way to monitor ototoxicity in patients receiving ami-
noglycoside therapy; the lack of consistent predictors 
of hearing loss is one of the shortcomings of research 
in human ototoxicity (Peloquin et  al. 2004). In general, 
hearing loss due to ototoxicity is ascertained by compar-
ing baseline data, ideally obtained before commencement 
of ototoxic drug administration, to the results obtained in 
subsequent monitoring tests (Duggal and Sarkar 2007). 
The duration of monitoring should extend for a reason-
able period otherwise the onset of the ototoxicity may be 
missed as it may start at the end of the aminoglycoside 
therapy with slow progression (Xie et al. 2011).
Hotz et al. (1994) have proposed the use of Transiently 
Evoked Oto-Acoustic emission (TEOAE) for early moni-
toring of aminoglycoside induced ototoxicity, based 
on the relation of TEOAE characteristics reflecting the 
integrity of the cochlea’s outer hair cell (OHC). However 
the American Speech-Language-Hearing Association 
(ASHA) recommends otherwise; though the sensitivity 
of TEOAE to the status of OHC was acknowledged the 
lack of specific guidelines to tailor its application to oto-
toxicity monitoring was highlighted as its main Achilles’ 
heel (ASHA 1994). Moreover, the presence of abnormal 
middle-ear function and a baseline hearing loss of greater 
than 40  dB HL (decibels hearing level) may preclude 
effective monitoring of ototoxicity with oto-acoustic 
emissions (Harris et al. 2012).
Serial audiometry-including high frequencies—dem-
onstrating change from baseline values in pure tone 
thresholds is probably the most effective method to prove 
ototoxic hearing loss (Duggal and Sarkar 2007). High fre-
quency thresholds is required in the audiometry because 
this range (>8 kHz) is usually first (but sometimes solely) 
affected in ototoxicity. Limiting hearing monitoring to 
the conventional-frequency range may potentially result 
in missing many cases of ototoxicity therefore the ASHA 
and the American Academy of Audiology (AAA) guide-
lines recommends high-frequency audiometry as the 
method of choice in early detection of ototoxicity (ASHA 
1994; AAA 2009). Additional measures should also be 
instituted to overcome other sources of errors in an oto-
toxicity screening program. Such measures will include: a 
thorough interview to identify other causes of conductive 
hearing loss from the medical history, full documentation 
of all drugs administered to subjects—even when such 
drugs are considered safe for hearing preservation—and 
a baseline audiogram to enable the subjects learn the test 
technique apart from providing a reference value for the 
hearing acuity (Duggal and Sarkar 2007). Since hearing 
loss due to aminoglycoside ototoxicity usually becomes 
manifest from the 5th day post commencement of drug 
treatment (De Jager and Van Altena 2002) post treatment 
screening should commence at least after a week of ther-
apy. It has also been advocated that screening takes place 
at least weekly during the course of the treatment (Dug-
gal and Sarkar 2007).
Other tests have also been advocated but critics have 
highlighted their shortcomings. Electro-cochleo-graphy 
(ECochG) requires an invasive technique to be very sen-
sitive and a long time to acquire frequency-specific data 
thus eliminating its usefulness in routine hearing moni-
toring (ASHA 1994). Auditory brainstem (ABR) evoked 
response share similar limitations with ECochG in 
respect of time required for testing (ASHA 1994).
Despite perceived advantages of other monitoring 
methods audiometry remains the most widely accepted 
technique. The sturdiness of audiometry equipment and 
wide availability even in developing countries in addition 
to its other benefits makes it an attractive option to be 
adopted in field work in Africa.
Vestibular assessment in ototoxicity
The true incidence of vestibular ototoxicity has been 
underestimated. Multiple factors are responsible for the 
lack of clear data on the true incidence of vestibular dam-
age following aminoglycoside exposure. A main factor is 
that subclinical vestibular damage is hard to document, 
another factor is that the initial destruction of vestibu-
lar hair cells also occurs outside the normal active and 
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passive head movement frequency range for the vestibu-
lar system.
Vigilance and prior anticipation of symptoms are the 
hallmarks of effective subjective evaluation of vestibular 
damage. Subjective evaluation of vestibular dysfunction 
involves recording complaints of dizziness, imbalance 
and oscillopsia made by the patient. Validated survey 
tools are also part of the armamentarium in subjective 
evaluation. A good example is the Dizziness Handicap 
Inventory (DHI) which allows subjects to evaluate on-
going well-being (Jacobson and Newman 1990).
There are multiple methods for objective evaluation of 
vestibular function but the main goal is to determine the 
normal function of the labyrinthine end-organ and the 
Central Nervous System (CNS) pathways via the vestib-
ulo-ocular reflex (VOR) (Kisilevsky et  al. 2004). Objec-
tive evaluations of vestibular function test the integrity 
of the VOR; these tests include electronystagmography 
(ENG), rotational chair, sacculocolic testing, vestibular 
evoked potentials, and computerized dynamic posturog-
raphy (CDP) (Kisilevsky et al. 2004). The advantages and 
disadvantages of each evaluation methods are shown in 
Table 1.
ENG is the recording of eye movements -it is the most 
available and widely used test of vestibular function (Kisi-
levsky et al. 2004) and is based on the principle of meas-
urement of changes in the corneo-retinal potential which 
occurs with eye movements with respect to electrodes 
placed around the eyes. There are multiple tests within 
the ENG test battery such as oculomotor test, measure-
ment of spontaneous nystagmus, positional testing and 
caloric testing. The gold standard for objective evaluation 
of unilateral vestibular deficit is caloric test. The main 
advantage of the caloric test is that it is the only vestibu-
lar function test that allows separate stimulation of each 
labyrinth. This makes the test highly sensitive for unilat-
eral peripheral vestibular lesions. The caloric test uses 
a thermal stimulus (water or air) to induce flow of the 
endolymph in the semi-circular canals (SCCs) through 
creation of a temperature gradient from one side of the 
canal to the other. The main canal tested is the horizontal 
SCC since it is the canal anatomically closet to the exter-
nal auditory canal and thus it develops the largest tem-
perature gradient (Kisilevsky et al. 2004).
The caloric test has handicaps which may restrict its 
use in aminoglycoside monitoring. Caloric testing is lim-
ited in bilateral vestibular loss which causes symmetri-
cally depressed caloric responses (Fee 1980). By design 
caloric testing only allows for low-frequency stimula-
tion. This is also limiting since the frequency of rotation 
obtainable with caloric stimulation is below the normal 
physiologic range of the vestibular system. This means a 
poor sensitivity and specificity of the caloric test for sym-
metric loss of vestibular function. Despite the handicaps 
the obvious advantages of the caloric test such as the ease 
of the test, the wide availability and portability of the 
equipment ensures that it remains a relevant tool in ves-
tibular function studies. Combining this test with subjec-
tive evaluation techniques will enable a good monitoring 
system for aminoglycoside toxicity.
Genetic mutations associated with ototoxicity
At very high cumulative drug levels most individuals will 
exhibit ototoxicity to aminoglycosides; while at lower 
cumulative drug levels, observed aminoglycoside ototox-
icity is probably a result of genetic susceptibility. Mito-
chondria DNA abnormality was noted by Higashi (1989) 
to be the likely basis of the maternal inheritance observed 
in familial aminoglycoside ototoxicity. This observation 
was buttressed when Hu et  al. (1991) described mater-
nal transmission in familial aminoglycoside ototoxicity 
in another set of related individuals. All these observa-
tions tended to confirm that mutation of mitochondrial 
genes was the likely molecular basis for aminoglycoside 
Table 1 Relative advantage and limitations of laboratory vestibular tests. Adapted from Kisilevsky et al. (2004)
CDP computerized dynamic posturography, ENG electronystagmography, SCC semi-circular canal
Laboratory vestibular test Advantages Disadvantages
ENG caloric Possibility of separate side stimulation
Availability
Highly sensitive for unilateral loss
Tests mainly lateral SCC
Non-physiologic stimulus
Low sensitivity in bilateral loss
Tests only low frequencies
Rotating chair Allows for high-frequency testing Physiologic stimulus
Allows differentiation between central and peripheral 
impairment
Bilateral simultaneous stimulation only Stimulation in hori-
zontal plane only
Lower than in caloric side sensitivity
CDP Assesses overall balance performance
Directly reflects ability of everyday activity
May identify abnormalities in case of normal ENG caloric
Useful in rehabilitation and quantification of overall bal-
ance
Unable to localize site of lesion within vestibular system
Possibility of “learning curve” in case of malingering
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ototoxicity (Fischel-Ghodsian 2004). Aminoglycosides 
exerted their antibacterial activity by direct binding to 
16S ribosomal RNA (rRNA) in the 30S subunit of the 
bacterial ribosome, thus causing mistranslation or pre-
mature termination of protein synthesis (Chamber and 
Sande 1996; Noller 1991). Accumulation of non-func-
tional and truncated proteins thus occurred leading 
eventually to bacterial death (Xie et al. 2011). This effect 
was usually limited to bacterial ribosomes because the 
affinity of aminoglycosides for eukaryotic ribosomes was 
lowered due to structural differences hence rendering 
the drug safe for humans (Xie et al. 2011). However since 
mitochondria were evolutionarily derived from bacteria, 
mitochondrial ribosomes therefore shared greater simi-
larities to bacterial ribosomes than their cytosolic coun-
terparts (Fischel-Ghodsian 2004; Guan 2004). Thus it has 
been suggested that aminoglycosides exerted their oto-
toxic activity at the mitochondrial ribosome.
The 12S rRNA ribosomal subunit binds to amino-
glycosides and it is known to confer resistance to ami-
noglycosides in the mitochondria of bacteria and yeast 
(Fischel-Ghodsian 2004). Several ototoxic mitochondria 
DNA (mtDNA) mutations in the 12S rRNA gene have 
been identified in patients with aminoglycoside ototox-
icity. Current reports indicated that at least five differ-
ent homoplasmic mutations in the mitochondrial gene 
encoding 12S rRNA (MT-RNR1) have been identified 
to predispose individuals to irreversible aminoglycoside 
induced hearing loss (Bardien et al. 2009). The homoplas-
mic A1555G mutation and C1494T mutation and muta-
tions at position 961 in the 12S rRNA gene have been 
associated with aminoglycoside-induced hearing loss 
(Matthijs et al. 1996; Usami et al. 1997); other identified 
mutations are T1095C and A827G (Thyagarajan et  al. 
2000; Xing et  al. 2006). The A1555G mutation was the 
first mutation to be described and the commonest vari-
ant seen (Bardien et al. 2009); it has been reported in dif-
ferent populations’ worldwide (Guan 2006). The A1555G 
mutation leads to increased binding of aminoglycosides 
to the 12S rRNA ribosomal subunit with subsequent 
disruption of mitochondrial protein synthesis and even-
tual cell death (Duggal and Sarkar 2007; Qian and Guan 
2009).
Identified genetic mutations appeared to be commoner 
in the black population. Studies in different populations 
have shown the A1555G mutation to be relatively rare; 
a frequency of 0.48, 0.09, and 0  % were seen in studies 
done in the general population of New Zealand, America 
and Argentina respectively (Scrimshaw et al. 1999; Tang 
et  al. 2002; Gravina et  al. 2007). A recent study among 
the Black population in South Africa however showed 
prevalence as high as 0.9  % (Bardien et  al. 2009). This 
might suggests that the mutation might be more frequent 
among Blacks compared to other human races. Both 
A1555G and C1494T mutations decrease translation 
accuracy in the mitochondrion. This makes the riboso-
mal decoding site highly susceptible to damage by ami-
noglycosides (Bardien et al. 2009; Hobbie et al. 2008).
Research goals
We hypothesize that the use of streptomycin based anti-
TB drug regimen is associated with ototoxicity and that 
there is an association between genetic mutations of 
12sRNA gene and development of streptomycin associ-
ated ototoxicity among West Africans.
Therefore the overall goal of this study is to determine 
the incidence of ototoxicity in a cohort of patients under-
going TB re-treatment and to determine any association 
between the genetic mutations in 12S rRNA mitochon-
dria gene and streptomycin induced hearing loss.
Specific objectives are: (1) determine the incidence 
of ototoxicity in a cohort of category II TB patients; (2) 
determine the probability of developing ototoxicity and 
the median onset time of ototoxicity; (3) determine the 
demographic and pharmacologic parameters associated 
with developing ototoxicity; (4) describe the mutations in 
the 12S rRNA gene in the cohort.
Methods
Study design
This study was approved by the Ethics Review Board of 
the Ministry of Health, Oyo state, Nigeria. Subjects will 
be recruited at the start of TB therapy and followed 
in a prospective longitudinal study till conclusion of 
treatment.
Eligible patients must meet the following criteria:
1. Diagnosis of TB and scheduled to commence TB re-
treatment with streptomycin based drug regimen;
2. Hearing thresholds of 60  dB or better on pure tone 
audiometry (PTA) before commencement of strepto-
mycin.
Excluded individuals will be those with:
1. Evidence of active infective pathology of the ear on 
examination;
2. Evidence of conductive hearing loss with an air-bone 
gap exceeding 10 dB on baseline PTA;
3. Asymmetric hearing exceeding 20  dB at any fre-
quency on baseline PTA;
4. Abnormal serum creatinine at baseline;
5. Concomitant use of other ototoxic drugs (mac-
rolides, diuretics, iron chelating drugs, chemotherapy 
drugs such as cisplatin and vinca alkaloids);
6. Evidence of confirmed HIV/AIDS infection.
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Study setting
Uncomplicated TB is managed in Nigeria at Directly 
Observed Therapy-Short course (DOTS) centers after 
diagnosis. These DOTs centers are located in primary 
health centers (PHC) within the community. PHCs are 
common in Nigerian towns and villages; they are sited 
with the goal of easy accessibility by the public. These 
centers are often manned by nurses, community health 
workers and community health extension workers. Initial 
diagnosis of TB (i.e. no prior treatment of TB) is desig-
nated as category I and managed with a 6 month regimen 
of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide. 
However patients who default from treatment or repre-
sent with a relapse of TB are designated as category II 
and commenced on 8  month regimen of anti-TB medi-
cations which include daily streptomycin injection in 
the first 2 months. The dosage varies with weight of the 
patient. (See Additional file  1 for recommended strep-
tomycin dosages by the National Tuberculosis and Lep-
rosy Control Program of Nigeria) Study subjects will be 
recruited from the category II patient pool.
Subjects will be recruited consecutively as diagnosis 
is made and consent given at the DOTS centers. Subse-
quent follow-up will also take place at the DOTS centers 
over the course of the treatment regimen. All the relevant 
socio-demographic and clinical data will be recorded 
using an interviewer administered modified question-
naire (Katijah et al. 2009). Additional information will be 
retrieved from patient case notes.
Sample size and power calculations
A recent study reported the proportion of TB patients 
with ototoxicity as 28 % (Sturdy et al. 2011). Assuming a 
5  % level of significance, a sample size of 150 would be 
able to estimate a prevalence of 28 % with a precision of 
±7.2  %, a prevalence of 50  % with a precision of ±8  %, 
and a prevalence of 5 % with a precision of ±3.5 %. The 
sample size will also allow the investigation of the asso-
ciation between ototoxicity and risk factors. For example, 
assuming a proportion with ototoxicity of 20 %, the study 
will be powered to detect an odds ratio of at least 2.5 if 
the prevalence of the risk factor in the population is at 
least 20 %. Adjustments of 10 % for loss to follow up gives 
a minimum sample size of 168 participants.
Study measures at baseline and follow‑up visit
Baseline pre-treatment full audiologic assessment will 
be performed on all the patients and repeated at com-
pletion of the TB treatment. Baseline and exit audio-
logic tests will include both air and bone-conduction 
threshold measurements in all the patients. Air conduc-
tion PTA will be done weekly during the intensive phase 
(2  months) and monthly during the continuation phase 
(6 months) till completion of the TB treatment. Enquiry 
on subjective hearing and balance changes will be sought 
from the subjects at every contact. Subjects who com-
plain of changes will undergo repeat full audiologic eval-
uation. The treatment guidelines of the WHO stipulate 
daily intramuscular streptomycin injection for category II 
TB patients (WHO 2010) therefore multiple dosing regi-
men of streptomycin will not be considered in this study.
Baseline pure tone audiograms between 250 and 
16,000  Hz will be performed for all the patients using 
a KUDU wave audiometer (Geoaxon, Pretoria, South 
Africa). This is a portable device run by an eMoyo algo-
rithm on a laptop and it obviates the need for a sound 
proof booth (Swanepoel et al. 2010). The audiometer uses 
external audio cups to attenuate environmental noise and 
intra-aural probe and fore head vibrator to deliver the 
pure tones. It also monitors ambient sound via an inbuilt 
microphone and the test is stopped once the environ-
mental sound becomes loud enough to interfere with the 
examination. A user friendly game pad is also attached to 
the laptop and user is instructed to press the keys after 
perceiving the pure tones. This enables the software to 
plot the user responses directly on an audiogram. The 
software also prompts the examiner to position the fore-
head vibrator after completion of the air conduction 
tests; at the end of both the bone and air conduction test 
the pure tone average is automatically calculated and a 
printer friendly audiogram is generated.
The quietest place in the DOTS center will be sought 
to perform the PTA. The vestibular function test (Romb-
erg Test) will be done in an examination room with an 
even floor and good lighting. The patient will be put at 
ease and the tests to be done fully explained in a language 
familiar to the patient. Assurances will be given that the 
examiner and research assistants will catch the patient 
and prevent a fall in case dizziness ensues in the course of 
the examination (see Table 2).
A panel of five homoplasmic mutations in the 12S 
rRNA gene previously described to predispose individu-
als to ototoxicity following aminoglycoside therapy will 
be investigated. These are: A1555G, 961delT  +  C(n), 
T1095C, C1494T and A827G (Bardien et  al. 2009). All 
subjects will have blood samples drawn and DNA will 
be extracted from whole blood samples using standard 
protocols. The DNA will be stored at −20 °C until batch 
testing is done. Genetic analysis for suspected mito-
chondrial polymorphisms will then be done on extracted 
DNA using standard protocols. Magnification of the 
mitochondrial DNA by PCR in 24 overlapping fragments 
will be done according to previously described protocol 
(Rieder et al. 1998). Direct sequencing of the PCR prod-
ucts will then be done with an ABI 3700 automated DNA 
sequencer; the sequences will be analyzed by comparison 
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with the reference sequences in the revised Cambridge 
reference sequence (rCRS) of the human mtDNA (acces-
sion no. AC_000021. 2) (Men et al. 2011).
Study outcomes
The criteria that will be used for identifying early oto-
toxic threshold shift from baseline audiogram are: (1) 
20 dB or greater decrease at any one test frequency, (2) 
10  dB or greater decrease at any two adjacent frequen-
cies, or (3) loss of response at three consecutive frequen-
cies where responses were previously obtained (ASHA 
1994; AAA 2009). All the pure tone threshold shifts will 
be recorded at each frequency tested with reference to 
the baseline pure tone threshold at the same frequency. 
All the changes will be confirmed by retest on the same 
day. The degree of ototoxicity will be graded according 
to the National Cancer Institute’s Common Terminol-
ogy Criteria for Adverse Events v4.3 (NCI 2010). Patients 
complaining of or showing audiological evidence of oto-
toxicity will be referred to the managing physicians for 
clinical review.
Statistical analysis
The data will be analyzed with Stata (Ver. 12) [Stata Corp, 
College Station, TX, USA]. Patient baseline character-
istics will be summarized with descriptive statistics and 
incidence rates of ototoxicity per 1000 person-years will 
be computed.
Person-time will be accrued from the date of recruit-
ment into the study until the earliest of: (1) development 
of ototoxicity; (2) loss to follow-up (defined as missing 
scheduled clinic visit and not returning during the study 
period); (3) transfer to another facility for any reason; or 
(4) completion of follow-up. For all patients, time zero 
will be the date of recruitment into the study.
Kaplan–Meier curves and the log-rank test will be used 
to compare progression to ototoxicity between groups. 
We will use Cox proportional hazards models to deter-
mine factors associated with development of ototoxic-
ity and also to examine for associations between the 
A1555G mutation in the 12sRNA gene and development 
of toxicity. The following variables will be measured and 
considered for inclusion in regression models: socio-
demographic variables like age, gender, weight, education 
and socio-economic status; clinical variables, BMI, total 
cumulative dose of strep, etc. The level of significance to 
be used is α = 0.05.
Discussion
This is a feasible prospective longitudinal study of strep-
tomycin induced ototoxicity in a developing country. The 
protocol has not yet been fully explored before in a study 
setting but we believe it is robust enough to achieve the 
set objectives. Recruiting and following up the patients 
from DOTS centers will ensure that there will be minimal 
loss to follow up. The incidence of TB in Nigeria is 133 
per 100,000 (Ibrahim et al. 2014); implying there will be a 
considerable population of TB patients that will progress 
to aminoglycoside based therapy.
Long distance to health centers have been identified 
as a reason for interruption of treatment of TB (Ibrahim 
et  al. 2014) therefore this study will utilize DOTS units 
nested within a primary health centers for recruitment of 
study participants. The primary health care centers are 
widely distributed within communities thereby ensur-
ing ease of access. Within these DOTS units drugs are 
provided free through a joint government and private 
donor’s initiative. The free drugs and ease of access to 
health care delivery point are incentives for patients to 
access treatment.
Despite the resurgence in incidence of TB in sub-
Saharan Africa and the relatively huge numbers of peo-
ple that will commence aminoglycoside based anti-TB 
drug regimen very little is known or being done about 
the ototoxicity that may arise from the aminoglycoside 
component of the drug regimen. It is possible that the 
auditory toxicities will have a negative impact on compli-
ance with treatment. If that is true it will impair efforts 
to control the disease in the society. The lack of clarity in 
patient counseling was identified as a deterrent to treat-
ment adherence in TB management (Ibrahim et al. 2014). 
Table 2 Measurement schedule
a Monthly assessment will be done once except clinical symptoms dictate 
otherwise
Measure Time point









 Questioning on vestibu-
lar symptoms
• • •
 Romberg • •
• •
• •
 Caloric irrigation testa •
Venipuncture
 Blood sample for 
genetic assay
•





 Medical history •
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Exploring the impact of aminoglycosides on the hearing 
and balance ability of patients will enable more accurate 
pre-treatment counseling sessions for patients. This will 
have a beneficial effect on treatment adherence. Data on 
genetic susceptibility will also benefit maternal relations 
of index participants when considering uptake of amino-
glycoside based therapy.
More importantly aminoglycosides are commonly 
used in many developing countries. This is likely due to 
their cheap manufacturing costs (Xie et  al. 2011) mak-
ing this class of antibiotics attractive in many economi-
cally disadvantaged societies. The unrestrained use of the 
drugs possibly contributes to the high burden of hear-
ing impairment in developing countries and probably a 
deafening of the population. Unlike in many developed 
societies where guidelines exists for monitoring serum 
concentrations when administering aminoglycosides 
such guidelines do not exist in many developing coun-
tries. Moreover there is lack of data to drive changes in 
policy regarding administration of aminoglycosides. 
Studying effects of streptomycin in tuberculosis patients 
therefore provides a unique opportunity to monitor ami-
noglycosides ototoxicity within the population in a devel-
oping country but the impact of the study will extend 
beyond tuberculosis treatment.
This study will provide insight into prevalence of oto-
toxicity in TB re-treatment and thus provide useful data 
for review of current treatment regimen and the contri-
bution of aminoglycoside induced ototoxicity to the bur-
den of hearing loss. It will also highlight areas requiring 
modification to improve treatment compliance in tuber-
culosis thereby providing evidence for appropriate pol-
icy formulation and resource allocation. The study will 
describe genetic mutations that predispose to aminogly-
coside induced ototoxicity within the study cohort. There 
is dearth of data on these mutations in the West African 
population thus emphasizing further the need for this 
study.
Conclusion
Hearing loss remains a chronic disability in many devel-
oping societies, reducing the burden of this disability 
requires a multi-dimensional strategy which will include 
policy shifts to tackle aminoglycoside ototoxicity.
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